Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label INX 189. Show all posts
Showing posts with label INX 189. Show all posts
Thursday, August 2, 2012

BMS-986094 (INX-189) Suspended HCV Study-on 'Serious' Issue

›
Aug 24 Updated - BMS halts the development of BMS-986094 due to patient death The original patient subsequently died and eight others suff...
Tuesday, June 26, 2012

Award-Professor Chris McGuigan/Bristol-Myers Squibb discuss development of new anti-viral drugs

›
Watch Professor Chris McGuigan of the Cardiff School of Pharmacy and Pharmaceutical Sciences and Bristol-Myers Squibb discuss the developm...
Thursday, January 12, 2012

Hepatitis C drug set to give Cardiff University financial boost

›
The drug has shown strong anti-viral activity, said Prof McGuigan A university behind a treatment for hepatitis C could reap "subs...
Monday, January 9, 2012

Idenix-Phase 2B trial of IDX184 Reports Positive Interim Data

›
Download PDF Idenix Reports Positive Interim Data for Hepatitis C Drug Idenix, which focuses on developing drugs to treat human viral disea...
Friday, November 4, 2011

INX-189 for Chronic Hepatitis C-Inhibitex Reports Corporate Developments

›
Inhibitex Reports Corporate Developments -4.25 log10 IU/mL Reduction in HCV RNA Levels Observed with Once-Daily Administration of 200 mg INX...
Monday, September 19, 2011

Monday HCV News Ticker;Patient Adherence to Hepatitis C Treatment

›
Handmade oil painting reproduction of Reading the News , one of the most famous James Tissot paintings. Patient Preferences and Assessment ...
Friday, April 1, 2011

EASL; INX-189 Positive Safety/Antiviral Data from Phase 1b Hepatitis C Study

›
Inhibitex Reports Positive Safety and Antiviral Data from Its Phase 1b Study of HCV Nucleotide Inhibitor INX-189 Potent Dose-Dependent An...